Research · Sep 3, 2026
[CYTK] Cytokinetics Thesis 2026: Aficamten HCM Drives Phase 3 Cardiac Myosin Cash Runway
Cytokinetics, Incorporated (NASDAQ: CYTK) FY2025 revenue ~$5-25M (pre-commercial) with adj. operating loss ~$(550-650M) + adj. EPS ~$(4.60-5.45) reflecting continued pre-commercial Aficamten (cardiac myosin inhibitor) pipeline (selected primary Aficamten Phase 3 SEQUOIA-HCM positive readout Q1 2024 + FDA acceptance Q4 2024 + expected oHCM FDA approval 2026-2027 + Aficamten MAVERICK-HCM nHCM Phase 3 + Aficamten ACACIA-HF HFpEF Phase 3) under continued President + CEO Robert Blum since 1998 (~27-year tenure as Cytokinetics CEO). One of the largest US specialty pre-commercial Cardiac Myosin Inhibitor + Muscle Activator biotech companies. Founded 1997 as Cytokinetics by Robert Blum + James Spudich + James Sabry + co-founders in South San Francisco California (~28-year heritage; selected pioneer Cardiac Myosin Inhibitor + Muscle Activator); selected post-April 2004 NASDAQ IPO; selected post-2004-2025 ~$3.5B+ cumulative equity + convertible notes raises; selected post-Q1 2024 Aficamten Phase 3 SEQUOIA-HCM positive readout; selected post-Q4 2024 Aficamten FDA submission acceptance; selected post-2023 Sanofi China Aficamten partnership. Headquartered in South San Francisco California; ~700-800 employees globally with ~25-30% Royalty Pharma + Forager Capital + RA Capital + institutional ownership concentration. One primary business: pre-commercial Cardiac Myosin Inhibitor + Muscle Activator biotech ~100%. Geographic mix: US ~95%+ + selected various aggregate international ~5%. Aficamten HCM Cardiac Myosin Inhibitor Phase 3 + FDA pipeline (key 2026 catalyst): selected continued post-Q1 2024 Aficamten Phase 3 SEQUOIA-HCM positive readout (oHCM); selected primary post-Q4 2024 FDA submission acceptance; selected primary expected FDA approval 2026-2027 (oHCM commercial launch); selected ~$3-5B US oHCM + nHCM + HFpEF TAM; selected ~$5-7B global HCM + HFpEF TAM; Bristol Myers Squibb Camzyos competitor; Aficamten differentiation lower QT prolongation + outpatient titration. MAVERICK-HCM + ACACIA-HF + Combo + Pediatric + International pipeline: selected continued post-2024 MAVERICK-HCM (nHCM Phase 3 enrolling; expected readout 2026-2027); selected ACACIA-HF (HFpEF Phase 3 enrolling); selected Aficamten Pediatric expansion; selected post-2023 Sanofi China Aficamten partnership + Bayer ex-US partnership exploration. President + CEO Robert Blum since 1998 (~27-year tenure); CFO Sung Lee. Capital position: ~$0 dividend (no dividend track post-1998 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025; net cash ~$0.95-1.20B aggregate cash + investments balance (~$1.5B+ cumulative equity + convertible notes raises); net leverage ~moderate-elevated (~$0.50-0.65B aggregate Convertible Notes); non-investment grade unrated credit; ~125-130M diluted shares. FY2026 thesis: Aficamten oHCM FDA approval 2026-2027 + Aficamten commercial launch + Aficamten MAVERICK-HCM nHCM Phase 3 readout + Aficamten ACACIA-HF HFpEF Phase 3 enrollment + commercial launch preparation + ~$3-5B US Cardiac Myosin Inhibitor TAM + ~$0.95-1.20B aggregate cash runway through FY2026-2027. Risks: Bristol Myers Squibb Camzyos (Mavacamten) competitive entrenchment + Edgewise Therapeutics + Pfizer + Novartis cardiac myosin inhibitor competitive displacement + Aficamten FDA approval timing considerations (delays = direct revenue + cash runway risk) + Aficamten MAVERICK-HCM nHCM Phase 3 readout timing considerations + Aficamten ACACIA-HF HFpEF Phase 3 readout timing considerations + commercial launch execution considerations + Royalty Pharma synthetic royalty financing overhang considerations + post-1998 Robert Blum CEO succession considerations + post-April 2004 NASDAQ IPO overhang considerations.